1.3 USD
0 (0%)
1.3098 USD
+0.01 (+0.75%)
We assign a fundamental rating of 1 out of 10 to PLRX. PLRX was compared to 190 industry peers in the Pharmaceuticals industry. PLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PLRX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year PLRX has reported negative net income.
- PLRX had a negative operating cash flow in the past year.
- PLRX had negative earnings in each of the past 5 years.
- In the past 5 years PLRX always reported negative operating cash flow.
1.2 Ratios
- PLRX has a Return On Assets of -69.03%. This is in the lower half of the industry: PLRX underperforms 70.16% of its industry peers.
- With a Return On Equity value of -94.04%, PLRX is not doing good in the industry: 61.26% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -94.04% | ||
| ROIC | N/A |
ROA(3y)-39.89%
ROA(5y)-35.54%
ROE(3y)-47.53%
ROE(5y)-41.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for PLRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- PLRX has more shares outstanding than it did 1 year ago.
- PLRX has more shares outstanding than it did 5 years ago.
- PLRX has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -4.57, we must say that PLRX is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -4.57, PLRX is doing worse than 63.35% of the companies in the same industry.
- A Debt/Equity ratio of 0.14 indicates that PLRX is not too dependend on debt financing.
- PLRX has a Debt to Equity ratio of 0.14. This is comparable to the rest of the industry: PLRX outperforms 49.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.57 |
ROIC/WACCN/A
WACC9.8%
2.3 Liquidity
- PLRX has a Current Ratio of 12.99. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
- PLRX's Current ratio of 12.99 is amongst the best of the industry. PLRX outperforms 81.15% of its industry peers.
- A Quick Ratio of 12.99 indicates that PLRX has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 12.99, PLRX belongs to the best of the industry, outperforming 81.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.99 | ||
| Quick Ratio | 12.99 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 13.77% over the past year.
- The Revenue for PLRX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)13.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.74%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- PLRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.90% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.08%
EPS Next 2Y12.63%
EPS Next 3Y18.81%
EPS Next 5Y5.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- PLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- PLRX's earnings are expected to grow with 18.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.63%
EPS Next 3Y18.81%
5. Dividend
5.1 Amount
- No dividends for PLRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PLIANT THERAPEUTICS INC / PLRX FAQ
What is the ChartMill fundamental rating of PLIANT THERAPEUTICS INC (PLRX) stock?
ChartMill assigns a fundamental rating of 1 / 10 to PLRX.
Can you provide the valuation status for PLIANT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to PLIANT THERAPEUTICS INC (PLRX). This can be considered as Overvalued.
What is the profitability of PLRX stock?
PLIANT THERAPEUTICS INC (PLRX) has a profitability rating of 0 / 10.
Can you provide the financial health for PLRX stock?
The financial health rating of PLIANT THERAPEUTICS INC (PLRX) is 4 / 10.
Can you provide the expected EPS growth for PLRX stock?
The Earnings per Share (EPS) of PLIANT THERAPEUTICS INC (PLRX) is expected to grow by 28.08% in the next year.